Restandardized. All trials preserved. Uniform structure applied.

==============================
CLINICAL TRIALS DATABASE
========================

TRIAL ID: NCT05234567
NAME: Phase III Study of Novel Immunotherapy for Non-Small Cell Lung Cancer
SPONSOR: National Cancer Institute
STATUS: Recruiting
PHASE: 3
CONDITION: Non-Small Cell Lung Cancer (Stage IIIB-IV)
PRIMARY OUTCOME: Overall survival at 2 years

INCLUSION:

* Age >=18
* Confirmed NSCLC
* Stage IIIB or IV
* ECOG 0-1
* Measurable disease (RECIST 1.1)
* Prior platinum therapy
* PD-L1 >=50 percent
* Adequate organ function (standard hematologic, renal, hepatic limits)
* Life expectancy >=3 months
* Tissue sample available

EXCLUSION:

* Active brain metastases
* Autoimmune disease needing treatment within 2 years
* Active infection
* Prior PD-1/PD-L1/CTLA-4 therapy
* Other malignancy within 3 years
* Pregnancy or breastfeeding
* HIV, HBV, HCV
* Interstitial lung disease
* Immunosuppressive medication
* Severe cardiovascular disease

CONTACT: [clinicaltrials@nci.gov](mailto:clinicaltrials@nci.gov) | 1-800-555-0199

---

TRIAL ID: NCT05432198
NAME: Early Intervention Study for Alzheimer’s Disease With Tau-Targeting Agent
SPONSOR: Alzheimer’s Disease Cooperative Study
STATUS: Recruiting
PHASE: 2
CONDITION: MCI due to AD, mild AD
PRIMARY OUTCOME: Change in CDR-SB at 18 months

INCLUSION:

* Age 55-85
* Diagnosis: MCI due to AD or mild AD
* MMSE 20-28
* CDR 0.5 or 1.0
* Positive amyloid and tau imaging or CSF biomarkers
* Stable AD meds if used
* Study partner required
* Adequate sensory ability
* English or Spanish fluency
* Willing for MRI/PET

EXCLUSION:

* Other major neurologic disease
* Major psychiatric disease
* Seizure disorder
* Significant head trauma
* Significant vascular disease on MRI
* Structural brain disease
* Anticoagulant use (except aspirin/clopidogrel)
* MRI contraindications
* Significant liver/kidney disease
* Recent cancer
* Substance abuse
* Recent investigational drug
* Interfering psychotropics
* Untreated B12/thyroid deficiency

CONTACT: [adcs-recruitment@ucsd.edu](mailto:adcs-recruitment@ucsd.edu) | 1-877-555-0334

---

TRIAL ID: NCT05654321
NAME: Biologic Therapy for Moderate to Severe Rheumatoid Arthritis
SPONSOR: Rheumatology Clinical Trials Consortium
STATUS: Recruiting
PHASE: 3
CONDITION: Rheumatoid Arthritis
PRIMARY OUTCOME: ACR50 at 24 weeks

INCLUSION:

* Age 18-75
* RA per 2010 ACR/EULAR
* Disease >=6 months
* Active disease (>=6 tender and swollen joints)
* Elevated CRP or ESR
* Inadequate response to methotrexate
* Stable methotrexate
* Stable steroids <=10 mg
* Stable NSAIDs
* TB negative
* Contraception if applicable

EXCLUSION:

* Other inflammatory arthritis
* Systemic involvement
* Prior biologic DMARDs
* Recent DMARDs other than methotrexate
* Recent corticosteroid injections
* Active or serious infection
* Opportunistic infection history
* TB
* HIV/HBV/HCV
* Lymphoproliferative disease or cancer
* Severe heart failure
* Demyelinating disease
* Live vaccine recently
* Pregnancy/lactation
* Abnormal labs (listed in original text)

CONTACT: [ra-trial@rheumatology-trials.org](mailto:ra-trial@rheumatology-trials.org) | 1-866-555-0445

---

TRIAL ID: NCT05789012
NAME: Prevention Trial of Anticoagulation for Atrial Fibrillation in Elderly Patients
SPONSOR: Cardiovascular Research Network
STATUS: Recruiting
PHASE: 4
CONDITION: Atrial Fibrillation (non-valvular)
PRIMARY OUTCOME: Stroke/systemic embolism/major bleeding at 2 years

INCLUSION:

* Age >=65
* Documented AF
* CHA2DS2-VASc >=2
* ECG-documented AF or sinus rhythm
* Not on anticoagulation or poorly controlled warfarin
* Electronic pill monitoring
* Smartphone or tablet
* Informed consent

EXCLUSION:

* Mechanical valve or mitral stenosis
* Recent stroke/TIA
* High bleeding risk (detailed in original text)
* Renal failure
* Liver disease
* Dual antiplatelet therapy
* Drug allergy
* Life expectancy <2 years
* Malignancy
* Poor adherence capability
* Pregnancy
* Recent trial participation
* Cognitive impairment (MMSE <24)

CONTACT: [afib-prevention@cardionet.org](mailto:afib-prevention@cardionet.org) | 1-800-555-0578

---

TRIAL ID: NCT07239323
NAME: Intracellularly Prepared CAR-T for Relapsed/Refractory Hematological Malignancies
SPONSOR: Chongqing Precision Biotech Co., Ltd
STATUS: Recruiting
PHASE: 1
CONDITION: B-ALL, B-cell NHL, Multiple Myeloma
PRIMARY OUTCOME: MTD and DLTs (28 days)

INCLUSION:

* Age >=18
* Relapsed/refractory hematologic malignancy
* ECOG 0-2
* Expected survival >=3 months
* Hematologic, renal, hepatic, cardiac, pulmonary function within specified limits
* Negative pregnancy test if applicable
* Contraception required
* Signed informed consent

EXCLUSION:

* Recent antitumor therapy
* HSCT within 3 months
* Other malignancies unless specified exceptions
* Prior VSV-G pseudotyped virus exposure
* Severe infections
* Significant cardiovascular disease
* Significant neurologic disease
* Recent surgery
* Live vaccines
* Severe allergies
* Inability for IV access
* Investigator judgment of unsuitability

CONTACT: [sanbin1011@163.com](mailto:sanbin1011@163.com) | +86 13187424131

---

TRIAL ID: NCT05923456
NAME: Adjuvant Therapy for High-Risk Melanoma
SPONSOR: Melanoma Research Alliance
STATUS: Recruiting
PHASE: 3
CONDITION: Stage IIIB-IIIC Melanoma (resected)
PRIMARY OUTCOME: Recurrence-free survival at 3 years

INCLUSION:

* Age >=18
* Confirmed melanoma
* Resected stage IIIB/IIIC
* Surgery within 12 weeks
* BRAF V600E/K positive
* ECOG 0-1
* Healed surgical site
* Adequate organ function
* Negative pregnancy test
* Contraception

EXCLUSION:

* Stage I, II, IV or unresectable III
* Mucosal/uveal melanoma
* Prior systemic therapy
* Autoimmune disease
* ILD or pneumonitis
* Second malignancy
* Brain metastases
* Infection
* HIV (low CD4 or detectable viral load)
* HBV/HCV
* Severe allergy to antibodies
* Significant cardiovascular disease
* Ophthalmologic risks (BRAF/MEK arm)
* Bleeding disorders
* Pregnancy/lactation
* Inability to swallow

CONTACT: [melanoma-adjuvant@mra-trials.org](mailto:melanoma-adjuvant@mra-trials.org) | 1-855-555-0612

==============================
END OF CLINICAL TRIALS DATABASE